Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Results of ELOQUENT-2 trial for treatment multiple myeloma

Joseph Mikhael • 2 Jun 2015
ASCO 2015
Multiple Myeloma Antibodies Dexamethasone Elotuzumab Lenalidomide

Dr Joseph Mikhael discusses the results of ELOQUENT-2, a phase 3, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in relapsed or refractory multiple myeloma.

More from Joseph Mikhael

2:10
IKEMA trial update: Isatuximab in MM
Joseph Mikhael • 21 Oct 2020
1:53
Transplantation for consolidation in multiple myeloma
Joseph Mikhael • 21 Oct 2020
3:08
Disparities between African American and Caucasian patients with MM
Joseph Mikhael • 21 Oct 2020
2:10
Mentorship in the virtual era
Joseph Mikhael • 21 Oct 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals